Claims for Patent: 9,126,932

Summary for Patent: 9,126,932

Title:	Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
Abstract:	The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.
Inventor(s):	Robert M. Jones, Daniel J. Buzard, Sangdon Han, Sun Hee Kim, Juerg Lehmann, Brett Ullman, Jeanne V. Moody, Xiuwen Zhu, Scott Stim
Assignee:	Arena Pharmaceuticals Inc
Application Number:	US14/048,768
Patent Claims:	1. A method for treating a disorder associated with the S1P1 receptor in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound selected from compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates and hydrates thereof: wherein: m is 1; n is 1 or 2; Y is N or CR1; Z is N or CR4; R1, R2, and R4 are each independently selected from the group consisting of H, C1-C6 alkoxy, C1-C6 alkyl, C1-C6 alkylamino, C1-C6 alkylsulfonyl, C1-C6 alkylthio, carboxamide, cyano, C3-C7 cycloalkoxy, C3-C7 cycloalkyl, C1-C6 haloalkoxy, C1-C6 haloalkyl, halogen, heteroaryl and heterocyclyl, wherein said C1-C6 alkyl and C1-C6 alkoxy are each optionally substituted with one or two substituents selected from C3-C7 cycloalkyl and halogen; and R3 is C3-C7 cycloalkyl; wherein said disorder associated with the S1P1 receptor is selected from the group consisting of: psoriasis, rheumatoid arthritis, acne, psoriatic arthritis, inflammatory bowel disease, Crohn's disease, transplant rejection, multiple sclerosis, biliary cirrhosis, systemic lupus erythematosus, ulcerative colitis, and type I diabetes. 2. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is multiple sclerosis. 3. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is psoriasis. 4. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is rheumatoid arthritis. 5. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is Crohn's disease. 6. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is psoriatic arthritis. 7. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is systemic lupus erythematosus. 8. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is ulcerative colitis. 9. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is inflammatory bowel disease. 10. The method according to claim 1, wherein said disorder associated with the S1P1 receptor is biliary cirrhosis. 11. The method according to claim 1, wherein the compound is selected from the following compounds and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclohexyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; 2-(7-(3-cyano-4-cyclohexylbenzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3yl)acetic acid; 2-(7-((6-cyclopentyl-5-(trifluoromethyl)pyridin-3-yl)methoxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; 2-(7-(4-cyclobutyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid; and 2-(7-(4-cyclopropyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 12. The method according to claim 1, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 13. The method according to claim 1, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 14. The method according to claim 1, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 15. The method according to claim 1, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 16. The method according to claim 1, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 17. The method according to claim 2, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 18. The method according to claim 2, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 19. The method according to claim 2, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 20. The method according to claim 2, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 21. The method according to claim 2, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 22. The method according to claim 10, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 23. The method according to claim 10, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 24. The method according to claim 10, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 25. The method according to claim 10, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 26. The method according to claim 10, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 27. The method according to claim 3, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 28. The method according to claim 3, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 29. The method according to claim 3, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 30. The method according to claim 3, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 31. The method according to claim 3, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 32. The method according to claim 4, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 33. The method according to claim 4, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 34. The method according to claim 4, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 35. The method according to claim 4, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 36. The method according to claim 4, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 37. The method according to claim 5, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 38. The method according to claim 5, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 39. The method according to claim 5, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 40. The method according to claim 5, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 41. The method according to claim 5, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 42. The method according to claim 6, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 43. The method according to claim 6, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 44. The method according to claim 6, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 45. The method according to claim 6, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 46. The method according to claim 6, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 47. The method according to claim 7, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 48. The method according to claim 7, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 49. The method according to claim 7, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 50. The method according to claim 7, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 51. The method according to claim 7, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 52. The method according to claim 8, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 53. The method according to claim 8, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 54. The method according to claim 8, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 55. The method according to claim 8, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 56. The method according to claim 8, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 57. The method according to claim 9, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: 2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 58. The method according to claim 9, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 59. The method according to claim 9, wherein the compound is selected from the following compound and pharmaceutically acceptable salts, solvates and hydrates thereof: (S)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 60. The method according to claim 9, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: Calcium salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid. 61. The method according to claim 9, wherein the compound is selected from the following salt and pharmaceutically acceptable solvates and hydrates thereof: L-Arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid.